Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy

Cancer

Volumn 79, Issue 5, 1997, Pages 952-962

  Bauer, John J ^a,c   Connelly, Roger R ^c   Sesterhenn, Isabell A ^b,c   Bettencourt, Marie Claude ^a,c   McLeod, David G ^a,c   Srivastava, Shiv ^c   Moul, Judd W ^a,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

bcl 2; Ki 67; p53; prostate carcinoma; prostatectomy; recurrence

Indexed keywords

KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; GENETIC MARKER; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTO ONCOGENE; RECURRENCE RISK; SEROLOGY; STATISTICAL MODEL;

AGED; CARCINOMA; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031047655     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970301)79:5<952::AID-CNCR12>3.0.CO;2-1     Document Type: Article

References (29)

1. Parker SI, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. CA Cancer J Clin 1996;46:5-27.
2. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate 1990;16:39-50.
3. Partin AW, Piantadosa S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45:831-7.
4. Lu-Yao GL, McLerran D, Wassou JH, Wensuberg IE. An assessment of radical prostatectomy: time trends, geographic variation and outcomes. JAMA 1993;269:2633-6.
5. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population based study. J Natl Cancer Inst 1996;88:166-72.
6. Soloway MS, Sharifi R, Wajsman Z, McLeod DG, Wood DP, Puras-Beaez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 1995;154:424-8.
7. Paulson DF, Moul JW, Robertson JE, Walter PJ. Postoperative radiotherapy of prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1990;143:1178.
8. Srivastava S, Katayose D, Tong YA, Craig CR, McLeod DG, Moul JW, et al. Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 1996;46:843.
9. Douglas TH, McCarthy WF, McLeod DG, Moul JW. Patient selection for experimental adjuvant therapy after radical prostatectomy.[letter to the editor]. Urology 1996;47:284-5.
10. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, et al. p53 expression and clinical outcome in prostate cancer. Br J Urol 1993;72:778-81.
11. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995;26:106-9.
12. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Can Res 1995;1:1295-1300.
13. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol. 1996;156:1511-6.
14. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is an independent prognostic marker of recurrence in patients with organ-confined prostate cancer after radical prostatectomy. J Urol 1996;156:1064-8.
15. Partin AW, Oesterling JE. The clinical usefulness of prostatic-specific antigen: update. J Urol 1994;152:1358-68.
16. Gleason DF. Histological grading and clinical staging of prostate carcinoma. In: Tannenbaum M. editor. Urologic pathology: the prostate. Philadelphia: Lea & Febinger, 1977:171-97.
17. Mostofi FK, Sesterhenn IA, Sobin LH. Histological typing of prostate tumors. Geneva: World Health Organization, 1980.
18. Obovi M, Wheeler TM, Scardino PT. The American Joint Committee on Cancer and International Union Against Cancer. TNM classification of prostate cancer. Cancer 1994; 73:104-14.
19. Cox DR. Regression models and life tables [with discussion]. J R Stat Soc Bull 1972;34:187-220.
20. Breslow NE. Statistical methods for censored survival data. Environ Health Perspect 1979;32:181-92.
21. Partin AW, Yao J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
22. Douglas TH, Snow PB, Connelly RR, Mcleod DG, Moul JW. Neural network analysis of pre-operative and post-operative variables to predict pathologic and recurrence outcome following radical prostatectomy. J Urol 1996; 155(Suppl):487, A# 706.
23. Stamey TA, Freiha FS, McNeal JE, Redvine EA, Whitemore AS, Schmid HP. Localized prostate cancer: relationship of tumor volume to clinical significance for the treatment of prostate cancer. Cancer 1993; 71(Suppl):933/8.
24. Moul JW, Sesterhenn IA, Connelly RR, Douglas TH, Srivastava S, Mostofi FH, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995;274:1277-81.
25. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti JC, Leidich R, et al. The role of transrectal ultrasound-guided biopsy based staging, pre-operative serum prostate-specific antigen, and biopsy. Gleason score is prediction of final pathologic diagnosis in prostate cancer. Urology 1995; 46:205-12.
26. Epstein JI, Pizov G, Walsh PC. Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93.
27. Norberg M, Holberg L, Wheeler T, Magnusson A. Five year follow-up after radical prostatectomy for localized prostate cancer: a study of the impact of different tumor variables on progression. Scand J Urol Nephrol 1994;28:391-9.
28. Ravery V, Boccon-Gibod LA, Meulemans A, Dauge-Geoffroy MC, Toublanc M, Boccon-Gibod L. Predictive value of pathological features for progression after radical prostatectomy. Eur Urol 1994;26:197-201.
29. Moul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 1996;155:1667-73.